Fresh analysis indicates that patients who discontinue popular GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass at a significantly accelerated pace than those who halt conventional lifestyle regimens.
Research printed in a leading health publication points out that while obese individuals often shed a large proportion of their body weight while on the medication, the weight comes back at an average rate of 0.8 kg per month once they quit.
"Users buying such treatments must be aware of the risk of fast weight regain when the therapy is stopped," cautioned lead investigator Dr. Susan Jebb.
That rate of regain implies a return to pre-treatment mass in about 18 months.
Analyzing Therapies
The research, which reviewed dozens of studies involving thousands of patients, contrasted the effects of GLP-1 agonists with older methods.
Researchers point out that individuals who shed pounds through lifestyle changes alone typically see a more gradual weight regain—approximately 100 grams monthly—post-intervention.
The Reason for the Fast Rebound
Nutrition scientists believe the mechanism of the injections explains the accelerated weight return.
The injections mimic a natural hormone called GLP-1, which controls feelings of fullness.
"Sustained high doses of GLP-1 concentrations far above than normal might result in the body to produce less of its endogenous hormone, and could lessen responsiveness to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Stopping of this GLP-1 'fix' results in hunger is no longer kept in check, making binge eating far more likely."
An Ongoing Condition?
Medical guidelines recommend the jabs for people with obesity-related health risks, accompanied by recommended diet and exercise modifications.
Professionals say that, considering the likelihood of weight regain, the treatment is often long-term.
This view is supported by pharmaceutical companies, who say that the results "emphasize the long-term nature of obesity," similar to managing diseases like hypertension.
User Testimonies
Users who have stopped the medication explain a intense return of hunger.
"It felt as if something activating and I was suddenly starving," recalled a patient.
The struggle is compounded if users have not adopted lasting dietary or behavioural changes during treatment.
Significant Adoption
Survey data show that millions of people in the UK have tried these injections in the last 12 months, with desire remaining high.
- Use is more common among women compared to men.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion access the drugs through private healthcare rather than public health services.
Ultimately, researchers caution that while GLP-1 drugs are powerful tools for weight loss, they are not a magic fix and lasting health benefits likely depends on combined lifestyle management.
